At present, a variety of NPs have been approved by the FDA for tumor treatment or are under preclinical or clinical investigation.[48, 49, 50] Herein, we developed a pH‐responsive NP to carry SERPINB3 siRNA combined with cisplatin for HPV‐negative PDX model treatment, which resulted in the effective downregulation of SERPINB3 in a PDX tumor model and exhibited a promising synergetic antitumor effect. The gene discussed is SERPINB3; the disease is neoplasm.